drugset
Drugs / CoTend-s3BXBB
last change Oct 2025 re-read 3 minutes ago

CoTend-s3BXBB

also known as SARS2-17032

Vaccine

Developed for
COVID-19
Investigated by
Kara Chew · National Institute of Allergy and Infectious Diseases (NIAID) · Tendel Therapies, Inc. · University of California, Davis · University of California, San Francisco

Trials 1

today NCT06810934 · Ph 1/2
202620272028
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/2 NCT06810934 Oct 2025 → Dec 2027 expected COVID-19 Kara Chew Recruiting No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as CoTend-s3BXBB ClinicalTrials.gov intervention name — accepted as the source's own label NCT06810934 ↗
Known as SARS2-17032 “Intervention: CoTend-s3BXBB (SARS2-17032) Dose: 1x10\^6 vp (0.5mL) IM once” NCT06810934 ↗
Modality Vaccine “Ad35-vectored s3-SARS-CoV-2 RBD (XBB.1.5) vaccine” NCT06810934 ↗
Route Intramuscular “IM once” NCT06810934 ↗